Tatva Chintan Pharma Chem Limited (TATVA)
₹1,944.00 +0.17% last close, 16 Oct
Q2 FY27 results
📅 Next results: 19 Oct 2026 (board meeting)Tatva Chintan Pharma Chem Limited's board meets on 19 Oct 2026 to consider its Q2 FY27 results (July-September 2026).
In its latest reported quarter, Q1 FY27, Tatva Chintan's revenue was ₹167 Cr (+42.8% year on year, +24.7% on the previous quarter), and net profit ₹16.0 Cr (+128.3% year on year); the operating margin was 19.3%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹167 | +42.8% | +24.7% |
| Operating profit | ₹32.3 | +90.0% | +15.3% |
| Net profit | ₹16.0 | +128.3% | +59.8% |
| EPS (₹) | 6.83 | +140.5% | +54.9% |
| Operating margin | 19.3% | — | — |
TATVA delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 45.23% of the TATVA shares traded on NSE were taken to delivery, against the stock's own 20-session average of 43.54%. That is close to its usual level.
Delivery in the last 5 sessions: 36.5% · 36.0% · 44.1% · 50.3% · 45.2%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Tatva Chintan Pharma Chem Limited submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate was issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited. The RTA confirmed that securities received for dematerialisation during the quarter were processed, verified, and listed on the exchanges within prescribed timelines. This is a standard quarterly administrative filing with no financial or operational impact.
- Compliance certificate filed for the quarter ended September 30, 2026
- Issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
- Processed by RTA MUFG Intime India Private Limited on October 03, 2026
Tatva Chintan Pharma Chem Limited concluded its 30th Annual General Meeting on September 25, 2026, where shareholders approved all 10 resolutions with overwhelming support (>99.9% votes in favour). Key resolutions passed included the adoption of FY26 financial statements, dividend declaration, re-appointment of Managing Director Chintan Shah for three years starting February 1, 2027, and approval to increase borrowing limits and asset charges under Section 180 of the Companies Act. A total of 1.83 crore votes were polled representing 78.36% of total voting capital.
- All 10 AGM resolutions passed with over 99.99% overall voting approval
- 78.36% of total shares voted, representing 1,83,29,172 polled votes
- Re-appointment of Managing Director Chintan Nitinkumar Shah approved for 3 years effective February 1, 2027
- Shareholders approved increases in borrowing limits and creation of charges under Section 180 of Companies Act
Tatva Chintan Pharma Chem Limited has notified the exchanges of a scheduled one-to-one virtual meeting with Ask Investment Managers Limited on September 23, 2026. The company stated that only publicly available information will be discussed and no unpublished price sensitive information (UPSI) will be shared. This routine institutional interaction follows Tatva's Q1 FY27 revenue of Rs 167.06 crore and net profit of Rs 15.98 crore.
- One-to-one virtual investor meeting scheduled for September 23, 2026
- Meeting participant is Ask Investment Managers Limited
- Company clarified that no UPSI or confidential information will be shared
- Filing submitted pursuant to Regulation 30 of SEBI LODR Regulations, 2015
Tatva Chintan Pharma Chem Limited has intimated an upcoming virtual one-on-one meeting with HSBC Securities and Capital Pvt. Ltd. scheduled for September 15, 2026. The meeting will strictly discuss publicly available information without sharing any unpublished price-sensitive information (UPSI). As this is a standard institutional interaction, it carries no direct impact on company operations or near-term earnings.
- Meeting scheduled with HSBC Securities and Capital Pvt. Ltd. on 15 September 2026
- Interaction will be conducted as a One to One Virtual Meeting
- The company confirmed no unpublished price sensitive information (UPSI) will be shared
- Filing submitted under Regulation 30 of SEBI LODR Regulations on 08 September 2026
CRISIL Ratings has upgraded Tatva Chintan Pharma Chem's long-term bank loan rating to 'CRISIL A-/Stable' from 'CRISIL BBB+/Stable' and its short-term rating to 'CRISIL A2+' from 'CRISIL A2'. The rating action applies to total bank loan facilities of Rs 245 crore, representing approximately 44% of TTM revenue (Rs 554 crore). This reflects improved creditworthiness, backed by a strong operational turnaround where TTM PAT reached Rs 50 crore compared to Rs 1.63 crore in FY25. The upgrade validates the company's financial resilience and low gearing (debt-to-equity of 0.16).
- Long-term bank facilities rating upgraded to CRISIL A-/Stable from CRISIL BBB+/Stable
- Short-term facility rating upgraded to CRISIL A2+ from CRISIL A2
- Total bank loan facilities rated stand at Rs 245 crore
- Rated facilities include Rs 85 crore with Citibank, Rs 60 crore with ICICI Bank, and Rs 40 crore with SBI
- The rating letter remains valid till March 31, 2027
Tatva Chintan Pharma Chem Limited has fixed Friday, September 11, 2026, as the record date to determine shareholder eligibility for the final dividend for FY 2025-26. The 30th Annual General Meeting (AGM) is scheduled for September 25, 2026, with the register of members closed from September 12 to September 25, 2026. Subject to shareholder approval at the AGM, the dividend payout will commence on or after October 1, 2026. The e-voting cut-off date is set for September 18, 2026.
- Record date for FY26 final dividend fixed as 11 September 2026
- 30th Annual General Meeting scheduled for 25 September 2026 at 04:00 p.m. IST via VC/OAVM
- Book closure period set from 12 September 2026 to 25 September 2026
- E-voting cut-off date established as 18 September 2026
- Dividend payout scheduled on or after 01 October 2026, subject to AGM approval
Tatva Chintan Pharma Chem Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 as part of its Annual Report. The filing confirms that Structure Directing Agents (SDAs) contributed 40.74% of turnover, followed by PASC at 33.05% and PTC at 23.12%. Exports accounted for 75% of total turnover across 30 countries. The report stated FY26 standalone turnover of ₹496.30 crore and net worth of ₹758.23 crore.
- Exports contributed 75% of total turnover, serving customers across 30 countries and 17 domestic states
- Product turnover mix: Structure Directing Agents (SDA) 40.74%, PASC 33.05%, PTC 23.12%, and ESS 2.03%
- Reported FY26 standalone turnover of ₹4,962.96 million (₹496.30 crore) and net worth of ₹7,582.29 million
- Permanent employee turnover rate increased to 49.79% in FY26 compared to 30.06% in FY25
- Total workforce stood at 363 permanent employees and 734 workers across 2 manufacturing plants
Tatva Chintan Pharma Chem Limited has issued the notice for its 30th Annual General Meeting (AGM) to be held on September 25, 2026. Key business includes adoption of FY26 financial results, dividend declaration, and re-appointment of Managing Director Chintan Nitinkumar Shah alongside Whole-time Directors Ajaykumar Patel and Shekhar Somani for 3-year tenures starting February 1, 2027. The company is also seeking shareholder approval to increase its borrowing limits under Section 180(1)(c) of the Companies Act, 2013.
- 30th AGM convened for Friday, September 25, 2026 at 4:00 PM IST via VC/OAVM.
- Proposed 3-year re-appointment of MD Chintan Nitinkumar Shah from February 1, 2027 to January 31, 2030.
- Proposed 3-year re-appointment of Whole-time Directors Ajaykumar Mansukhlal Patel and Shekhar Rasiklal Somani from February 1, 2027.
- Special resolution tabled to approve an increase in borrowing limits under Section 180(1)(c).
Tatva Chintan Pharma Chem Limited has announced the resignation of Mr. Ajay Rawat, Assistant Vice President – Research and Development (designated as Senior Management Personnel). The resignation letter was submitted on 14 August 2026 and accepted by the company on 19 August 2026. His cessation will take effect from the close of business hours on 13 November 2026, providing a standard transition period.
- Mr. Ajay Rawat tendered his resignation via letter dated 14 August 2026
- Management accepted the resignation on 19 August 2026
- Cessation will take effect from close of business hours on 13 November 2026
Tatva Chintan Pharma Chem Limited announced the resignation of Senior Management Personnel Mr. Ajay Rawat, Assistant Vice President – Research and Development. The resignation letter was submitted on 14 August 2026 and accepted by management on 19 August 2026. His cessation will be effective from the close of business hours on 13 November 2026.
- Mr. Ajay Rawat resigned from the role of Assistant Vice President – Research and Development
- Resignation letter tendered on 14 August 2026 and accepted on 19 August 2026
- Cessation becomes effective at the close of business hours on 13 November 2026
Tatva Chintan Pharma Chem has issued a formal communication regarding Tax Deduction at Source (TDS) for its final dividend of ₹2.00 per share for FY 2025-26. The dividend, recommended by the Board on May 16, 2026, represents a 20% payout on the face value of ₹10. Resident shareholders will be subject to a 10% TDS if the total dividend exceeds ₹10,000, while non-residents face a 20% withholding tax, subject to Double Taxation Avoidance Agreement (DTAA) benefits. This follows a significant recovery in FY26, where the company reported a PAT of ₹39.08 Cr compared to just ₹1.63 Cr in FY25.
- Final dividend of ₹2.00 per equity share (20% of face value) recommended for the financial year ended March 31, 2026.
- Standard TDS rate of 10% applicable for resident shareholders with valid PAN, provided the dividend exceeds ₹10,000.
- Higher TDS rate of 20% will be applied for shareholders with invalid PAN or those who have not linked PAN with Aadhaar.
- Non-resident withholding tax rate set at 20% (plus surcharge and cess), with an option to claim lower rates under DTAA by submitting Form 41.
- The dividend is subject to approval by shareholders at the upcoming 30th Annual General Meeting (AGM).
Tatva Chintan Pharma Chem Limited has scheduled one-to-one virtual meetings with Ambit Global Private Client and TA Associate on August 12, 2026. These meetings come after a year of significant financial recovery, with FY26 revenue reaching ₹496.30 Cr, up from ₹368.31 Cr in FY25. The company will discuss publicly available information, focusing on its current operations and business environment. Such interactions are standard for maintaining institutional investor relations and do not involve sharing unpublished price-sensitive information.
- Two one-to-one virtual meetings scheduled for August 12, 2026
- Institutional participants include Ambit Global Private Client and TA Associate
- Company reported a TTM revenue of ₹496 Cr and PAT of ₹39 Cr for FY26
- Current manufacturing capacity stands at 280 KL across 13 assembly lines
Tatva Chintan Pharma Chem Limited has scheduled virtual one-on-one meetings with two institutional entities, Ambit Global Private Client and TA Associate, on August 12, 2026. These interactions follow a strong FY26 performance where revenue reached Rs 496.3 Cr, a significant recovery from Rs 368.3 Cr in FY25. The company currently trades at a high P/E of 95.6, indicating high market expectations for its expanded 280 KL manufacturing capacity. No unpublished price-sensitive information (UPSI) is expected to be shared during these routine investor relations sessions.
- Scheduled 2 one-on-one virtual meetings with institutional investors on August 12, 2026
- Company is leveraging an expanded manufacturing capacity of 280 KL across 13 assembly lines
- TTM Revenue stands at Rs 496 Cr with an improved Operating Profit Margin of 18.5%
- Promoter holding remains stable at 72.02% as of March 2026
Tatva Chintan Pharma Chem Limited has scheduled a one-to-one virtual meeting with Mahindra Manulife Investment Management Private Limited for August 6, 2026. This meeting follows a strong recovery in FY26, where revenue reached ₹496 Cr and PAT rebounded to ₹39 Cr from just ₹1.63 Cr in FY25. The company stated that no unpublished price sensitive information (UPSI) will be shared during the interaction. Such meetings are standard practice for mid-cap companies to engage with institutional investors regarding publicly available performance data.
- One-to-one virtual meeting scheduled for August 6, 2026
- Participant identified as Mahindra Manulife Investment Management Private Limited
- Company reported a TTM revenue of ₹496 Cr for FY26
- Current aggregate manufacturing capacity stands at 280 KL across 13 assembly lines
Tatva Chintan Pharma Chem Limited has scheduled a one-on-one virtual meeting with ChrysCapital Associates LLP for August 6, 2026. This is a routine regulatory disclosure under SEBI (LODR) Regulations. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during the interaction. This meeting comes as the company manages a recovery in FY26, with TTM revenue reaching Rs 496 Cr and PAT improving to Rs 39 Cr from a low base in FY25.
- One-to-one virtual meeting scheduled for August 6, 2026
- Interaction is specifically with ChrysCapital Associates LLP
- Company reported a TTM revenue of Rs 496 Cr as of the latest financial context
- Current aggregate manufacturing capacity stands at 280 KL with 13 assembly lines
- FY26 PAT recovered to Rs 39.08 Cr compared to Rs 1.63 Cr in FY25
Financial Performance
Revenue Growth by Segment
Consolidated revenue for FY25 was INR 385.03 Cr, reflecting a 3.99% YoY decline. The SDA (Structure Directing Agents) segment, a high-margin business, recorded sales of INR 119.72 Cr. However, H1FY26 showed a recovery with revenue reaching INR 240.4 Cr, a 27% increase compared to INR 189.0 Cr in H1FY25.
Geographic Revenue Split
Exports accounted for 61.53% of revenue (INR 235.47 Cr) in FY25, down from 70.36% (INR 276.86 Cr) in FY24. Domestic sales increased to 38.47% (INR 144.43 Cr) from 28.88% (INR 113.63 Cr) in the previous year, indicating a shift toward the Indian market amidst global demand volatility.
Profitability Margins
Standalone Profit After Tax (PAT) margin plummeted to 1.56% (INR 5.71 Cr) in FY25 from 8.01% (INR 30.35 Cr) in FY24. This 81.18% decline in PAT was driven by lower sales in the high-margin SDA segment and increased competition.
EBITDA Margin
EBITDA margin for H1FY26 improved to 16.0% from 10.0% in H1FY25, a 600 bps increase. Historical operating margins have fluctuated between 9.49% and 26% over the last five years due to raw material price volatility.
Capital Expenditure
The company made a net addition of INR 76.13 Cr to fixed assets in FY25. Total R&D-related CAPEX for the fiscal year was INR 8.43 Cr, aimed at strengthening the product pipeline for emerging opportunities.
Credit Rating & Borrowing
CRISIL reaffirmed the 'CRISIL A-' rating with a 'Stable' outlook (upgraded from Negative). Interest coverage ratio remains high at 28.3 times, and bank limit utilization is low at 5.33%, indicating strong debt-servicing capability.
Operational Drivers
Raw Materials
Primary raw materials are crude oil derivatives, which are highly susceptible to global price fluctuations. These materials constitute a significant portion of the cost structure, with operating margins swinging by over 16% historically based on procurement costs.
Import Sources
Sourced from diverse geographies across 30+ countries to mitigate localized supply disruptions. The company utilizes its wholly-owned subsidiaries, Tatva Chintan USA Inc. and Tatva Chintan Europe B.V., to manage international logistics and sourcing.
Capacity Expansion
Current aggregate manufacturing capacity stands at 280 KL with 13 assembly lines, following an expansion from 160 KL and 10 assembly lines. The company operates facilities in Ankleshwar (Zero Liquid Discharge) and Dahej SEZ.
Raw Material Costs
Raw material costs are a major component of the INR 221.97 Cr cost of materials consumed in FY25. Profitability is highly sensitive to these costs, as seen in the moderation of margins when SDA segment sales (which use specific high-value inputs) decline.
Manufacturing Efficiency
The company utilizes integrated and fungible manufacturing facilities, allowing for production flexibility across different product categories like SDAs and PTCs based on market demand.
Logistics & Distribution
Debtors turnover ratio declined to 4.60 in FY25 from 5.59 in FY24, primarily due to higher sales in Q4 FY25, resulting in year-end receivables of approximately 79 days.
Strategic Growth
Expected Growth Rate
27%
Growth Strategy
Growth will be driven by the commercialization of new products in FY26, leveraging the expanded 280 KL capacity, and increasing domestic market penetration (which grew 27% in FY25). The company is also focusing on high-value R&D products for the Pharma and Agrochemical sectors.
Products & Services
Structure Directing Agents (SDAs), Phase Transfer Catalysts (PTCs), Electrolyte Salts for supercapacitor batteries, and specialty chemicals for Pharma, Agrochemicals, Dyes, and Paints.
Brand Portfolio
Tatva Chintan
New Products/Services
The company is entering the commercial phase of new products in FY26, which are expected to be crucial for improving the business risk profile and margin recovery.
Market Expansion
Targeting expansion in over 30 countries with a focus on increasing the share of domestic sales, which rose to INR 144.43 Cr in FY25.
Strategic Alliances
Maintains wholly-owned subsidiaries in the USA (Tatva Chintan USA Inc.) and Europe (Tatva Chintan Europe B.V.) to act as marketing and distribution arms.
External Factors
Industry Trends
The specialty chemical industry is seeing a shift toward sustainable 'green' chemistry. Tatva Chintan is positioned for this through its 'zero liquid effluent discharge' facility and R&D focus on high-value, sustainable products.
Competitive Landscape
Faces increased competition in the SDA segment, which pressured margins in FY25, though it remains a leading player in the niche specialty chemicals space.
Competitive Moat
The moat is built on in-house R&D capabilities, fungible manufacturing lines, and deep-rooted relationships with global marquee clients. Sustainability is supported by the high entry barriers in the SDA and PTC segments.
Macro Economic Sensitivity
Highly sensitive to global economic slowdowns, which can plummet revenues across end-user sectors like Pharma, Agrochemicals, and Paints.
Consumer Behavior
Shift toward high-performance electronics and green energy is driving demand for the company's electrolyte salts used in supercapacitor batteries.
Geopolitical Risks
Widespread geographical presence in 30+ countries exposes the company to diverse regulatory changes and trade barriers, managed through stringent compliance with international ISO standards.
Regulatory & Governance
Industry Regulations
Complies with stringent manufacturing standards and drug manufacturing licenses from the Food and Drugs Control Administration, Gujarat.
Environmental Compliance
Maintains Zero Liquid Effluent Discharge at the Ankleshwar facility and holds ISO 14001:2015 certification for environmental management.
Taxation Policy Impact
The effective tax rate for FY25 was approximately 24.6%, with total tax expenses of INR 1.87 Cr on a Standalone Profit Before Tax of INR 7.58 Cr.
Legal Contingencies
The company has disclosed pending litigations in Note 46 of its financial statements; however, it does not anticipate material foreseeable losses from long-term or derivative contracts.
Risk Analysis
Key Uncertainties
The primary uncertainty is the timing of the demand recovery in the SDA segment, which could impact cash accruals if they fall below INR 2.5 Cr per month.
Geographic Concentration Risk
61.53% of revenue is concentrated in international markets, making the company vulnerable to global trade cycles and shipping disruptions.
Third Party Dependencies
Dependency on suppliers for crude oil derivatives is a risk, mitigated by maintaining diverse sourcing across different geographies.
Technology Obsolescence Risk
Mitigated by continuous R&D investment (INR 12.83 Cr in FY25) to ensure the product pipeline remains relevant for evolving customer preferences.
Credit & Counterparty Risk
Receivables are monitored closely, though debtor days increased due to high Q4 sales, with a year-end debtor balance reflecting a turnover ratio of 4.60.